Tiziana Life Sciences Ltd logo

Tiziana Life Sciences LtdNASDAQ: TLSA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

20 November 2018

Next earnings report:

27 December 2024

Last dividends:

N/A

Next dividends:

N/A
$101.74 M
-33%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-33%vs. 3y high
100%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 9 min ago
$0.98+$0.03(+3.15%)

Dividend

No data over the past 3 years
No data over the past 3 years
No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

TLSA Latest News

Tiziana Life Sciences secures grant for ALS trial
proactiveinvestors.com19 November 2024 Sentiment: -

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its grant application to the ALS Association has been approved. The company has secured funding under the Hoffman ALS Clinical Trial Awards Program which will be used for a 20-patient study investigating the safety and early efficacy of its investigational drug intranasal foralumab in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.

Tiziana Life Sciences CEO discusses foralumab potential to enhance Ozempic - ICYMI
proactiveinvestors.com02 November 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) this week announced positive research findings showing the anti-inflammatory potential of the company's nasal anti-CD3 antibody foralumab when used in combination with semaglutide, a GLP-1 agonist marketed as Ozempic and Wegovy. CEO Ivor Elrifi joined Proactive to discuss the findings.

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million
globenewswire.com30 October 2024 Sentiment: POSITIVE

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million

Tiziana Life Sciences awarded $4M to advance Alzheimer's disease research
proactiveinvestors.com19 September 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has secured a $4 million grant from the National Institutes of Health (NIH) to advance research of nasal anti-CD3 as a treatment for Alzheimer's disease. The company has been developing a fully human, anti-CD3 monoclonal antibody called intranasal foramulab, which has demonstrated a favorable safety profile and clinical response in studies to date.

Tiziana Life Sciences secures $3.4M in non-dilutive funding
proactiveinvestors.com28 June 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced it has received non-dilutive funding of $3.4 million which will be used to advance its investigation therapy foralumab. The company highlighted that foralumab is the only fully human anti-CD3 monoclonal antibody (mAb), which binds to the T cell receptor and dampens inflammation by modulating T cell function, therefore suppressing effector features in multiple immune cell subsets.

Tiziana Receives $3.4 Million in Non-Dilutive Funding
globenewswire.com28 June 2024 Sentiment: POSITIVE

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non-dilutive funding of $3.4 million and issued a corporate update video available here.

Tiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapy
proactiveinvestors.com26 June 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has won approval from the US Food and Drug Administration under an Expanded Access IND to dose its first patient with moderate Alzheimer's disease with its investigational therapeutic intranasal foralumab. Expanded access INDs allow patients to gain access to investigational drugs, biologics and medical devices to treat serious diseases and conditions for which there are no comparable or satisfactory therapy options outside of clinical trials, the biopharmaceutical company said.

Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with Foralumab
globenewswire.com26 June 2024 Sentiment: POSITIVE

NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer's disease.

Tiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trial
proactiveinvestors.com04 June 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it along with its research partners at Mass General Hospital have been invited to apply for a prestigious grant from the ALS Association to fund a clinical trial evaluating its asset intranasal foralumab. The company said the grant is offered as part of the Hoffman ALS Clinical Trial Awards Program, which helps develop new and improved therapies for ALS by supporting early-stage clinical trials.

Tiziana Life Sciences' chief advisor to receive "Giants of MS" award
proactiveinvestors.co.uk30 May 2024 Sentiment: POSITIVE

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the Chairman of its Scientific Advisory Board, Howard L  Weiner, is to receive the “Giants of MS” award. The award ceremony will be held on May 30, 2024, during the Consortium of Multiple Sclerosis Centers annual meeting in Nashville, Tennessee.

  • 1(current)
  • 2
  • 3

What type of business is Tiziana Life Sciences Ltd?

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

What sector is Tiziana Life Sciences Ltd in?

Tiziana Life Sciences Ltd is in the Healthcare sector

What industry is Tiziana Life Sciences Ltd in?

Tiziana Life Sciences Ltd is in the Biotechnology industry

What country is Tiziana Life Sciences Ltd from?

Tiziana Life Sciences Ltd is headquartered in United Kingdom

When did Tiziana Life Sciences Ltd go public?

Tiziana Life Sciences Ltd initial public offering (IPO) was on 20 November 2018

What is Tiziana Life Sciences Ltd website?

https://www.tizianalifesciences.com

Is Tiziana Life Sciences Ltd in the S&P 500?

No, Tiziana Life Sciences Ltd is not included in the S&P 500 index

Is Tiziana Life Sciences Ltd in the NASDAQ 100?

No, Tiziana Life Sciences Ltd is not included in the NASDAQ 100 index

Is Tiziana Life Sciences Ltd in the Dow Jones?

No, Tiziana Life Sciences Ltd is not included in the Dow Jones index

When was Tiziana Life Sciences Ltd the previous earnings report?

No data

When does Tiziana Life Sciences Ltd earnings report?

The next expected earnings date for Tiziana Life Sciences Ltd is 27 December 2024